Switch theme
Sign up to access all valuation multiples
Vertex Pharmaceuticals is a global biotechnology company that discovers and develops small-molecule drugs for the treatment of serious diseases. Its key drugs are Kalydeco, Orkambi, Symdeko, and Trikafta/Kaftrio, and Alyftrek for cystic fibrosis, where Vertex therapies remain the standard of care globally. Vertex has diversified its portfolio through Casgevy, a gene-editing therapy for beta thalassemia and sickle-cell disease, and Journavx, a non-opioid pain medication approved for the treatment of moderate-to-severe acute pain in adults. Additionally, Vertex is evaluating small-molecule inhibitors of APOL1-mediated kidney diseases. Vertex is also investigating cell therapies to deliver a potential functional cure for type 1 diabetes.
1989
6.1K+
LTM Revenue $11.4B
LTM EBITDA $2.7B
$109B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Vertex Pharmaceuticals has a last 12-month revenue (LTM) of $11.4B and a last 12-month EBITDA of $2.7B.
In the most recent fiscal year, Vertex Pharmaceuticals achieved revenue of $11.0B and an EBITDA of $486M.
Vertex Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Vertex Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $11.4B | XXX | $11.0B | XXX | XXX | XXX |
| Gross Profit | $9.9B | XXX | $9.5B | XXX | XXX | XXX |
| Gross Margin | 87% | XXX | 86% | XXX | XXX | XXX |
| EBITDA | $2.7B | XXX | $486M | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 4% | XXX | XXX | XXX |
| EBIT | $2.6B | XXX | $4.4B | XXX | XXX | XXX |
| EBIT Margin | 23% | XXX | 40% | XXX | XXX | XXX |
| Net Profit | $2.0B | XXX | -$536M | XXX | XXX | XXX |
| Net Margin | 18% | XXX | -5% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Vertex Pharmaceuticals's stock price is $442.
Vertex Pharmaceuticals has current market cap of $114B, and EV of $109B.
See Vertex Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $109B | $114B | XXX | XXX | XXX | XXX | $7.69 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Vertex Pharmaceuticals has market cap of $114B and EV of $109B.
Vertex Pharmaceuticals's trades at 9.9x EV/Revenue multiple, and 224.1x EV/EBITDA.
Equity research analysts estimate Vertex Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Vertex Pharmaceuticals has a P/E ratio of 56.8x.
See valuation multiples for Vertex Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $114B | XXX | $114B | XXX | XXX | XXX |
| EV (current) | $109B | XXX | $109B | XXX | XXX | XXX |
| EV/Revenue | 9.6x | XXX | 9.9x | XXX | XXX | XXX |
| EV/EBITDA | 39.7x | XXX | 224.1x | XXX | XXX | XXX |
| EV/EBIT | 41.3x | XXX | 24.8x | XXX | XXX | XXX |
| EV/Gross Profit | 11.1x | XXX | n/a | XXX | XXX | XXX |
| P/E | 56.8x | XXX | -211.9x | XXX | XXX | XXX |
| EV/FCF | 82.0x | XXX | -111.4x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialVertex Pharmaceuticals's last 12 month revenue growth is 9%
Vertex Pharmaceuticals's revenue per employee in the last FY averaged $1.8M, while opex per employee averaged $0.8M for the same period.
Vertex Pharmaceuticals's rule of 40 is 56% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Vertex Pharmaceuticals's rule of X is 48% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Vertex Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 9% | XXX | 10% | XXX | XXX | XXX |
| EBITDA Margin | 24% | XXX | 4% | XXX | XXX | XXX |
| EBITDA Growth | 121% | XXX | 10% | XXX | XXX | XXX |
| Rule of 40 | 56% | XXX | 14% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 48% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $1.8M | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $0.8M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 33% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 46% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| Armata Pharmaceuticals | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Vertex Pharmaceuticals acquired XXX companies to date.
Last acquisition by Vertex Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Vertex Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Vertex Pharmaceuticals founded? | Vertex Pharmaceuticals was founded in 1989. |
| Where is Vertex Pharmaceuticals headquartered? | Vertex Pharmaceuticals is headquartered in United States of America. |
| How many employees does Vertex Pharmaceuticals have? | As of today, Vertex Pharmaceuticals has 6.1K+ employees. |
| Who is the CEO of Vertex Pharmaceuticals? | Vertex Pharmaceuticals's CEO is Dr. Reshma Kewalramani, M.D.. |
| Is Vertex Pharmaceuticals publicy listed? | Yes, Vertex Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Vertex Pharmaceuticals? | Vertex Pharmaceuticals trades under VRTX ticker. |
| When did Vertex Pharmaceuticals go public? | Vertex Pharmaceuticals went public in 1991. |
| Who are competitors of Vertex Pharmaceuticals? | Similar companies to Vertex Pharmaceuticals include e.g. Julphar, Galapagos, Pharming, Vivoryon Therapeutics. |
| What is the current market cap of Vertex Pharmaceuticals? | Vertex Pharmaceuticals's current market cap is $114B |
| What is the current revenue of Vertex Pharmaceuticals? | Vertex Pharmaceuticals's last 12 months revenue is $11.4B. |
| What is the current revenue growth of Vertex Pharmaceuticals? | Vertex Pharmaceuticals revenue growth (NTM/LTM) is 9%. |
| What is the current EV/Revenue multiple of Vertex Pharmaceuticals? | Current revenue multiple of Vertex Pharmaceuticals is 9.6x. |
| Is Vertex Pharmaceuticals profitable? | Yes, Vertex Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Vertex Pharmaceuticals? | Vertex Pharmaceuticals's last 12 months EBITDA is $2.7B. |
| What is Vertex Pharmaceuticals's EBITDA margin? | Vertex Pharmaceuticals's last 12 months EBITDA margin is 24%. |
| What is the current EV/EBITDA multiple of Vertex Pharmaceuticals? | Current EBITDA multiple of Vertex Pharmaceuticals is 39.7x. |
| What is the current FCF of Vertex Pharmaceuticals? | Vertex Pharmaceuticals's last 12 months FCF is $1.3B. |
| What is Vertex Pharmaceuticals's FCF margin? | Vertex Pharmaceuticals's last 12 months FCF margin is 12%. |
| What is the current EV/FCF multiple of Vertex Pharmaceuticals? | Current FCF multiple of Vertex Pharmaceuticals is 82.0x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
